Skip to content
  • Home
  • Media
  • News
  • 2023 Globally known professor and dermatologist joins LEO Pharma

Globally known professor and dermatologist joins LEO Pharma

Ahead of EADV, LEO Pharma announces that Professor Alexander Egeberg, a board-certified dermatologist, and top key opinion leader, will join the company as Head of Global Medical Affairs.

BALLERUP, Denmark, October 9, 2023 – LEO Pharma A/S, a global leader in medical dermatology, is today announcing the appointment of Professor Alexander Egeberg, a globally recognized dermatologist and top key opinion leader as the company’s new Vice President, Head of Global Medical Affairs. The announcement happens ahead of the upcoming 32nd European Academy of Dermatology and Venereology (EADV) Congress.


Alexander Egeberg joins LEO Pharma from a role as Professor of Dermatology at the University of Copenhagen and head of one of the largest clinics in Northern Europe for biologic therapy at Bispebjerg Hospital's Department of Dermatology. He is a globally known professor and a board-certified dermatologist with an extensive research and clinical background. Having authored over 300 international scientific publications, he is an expert in inflammatory skin diseases with extensive experience in epidemiology, real-world evidence, translational medicine, and clinical trials. In addition, Alexander has through his work in Medial Affairs at Pfizer and as a consultant for additional global pharma companies built a solid understanding of corporate pharma.


The appointment of Professor Egeberg cements LEO Pharma’s commitment to medical dermatology and to integrate the clinicians and patients’ voices at the core of the organization.


Professor Alexander Egeberg comments:

“I am genuinely excited to join LEO Pharma as Vice President, Head of Global Medical Affairs. Medical dermatology is a rapidly evolving field, yet there are still many diseases with few or no good treatment options. LEO Pharma has a proud 115-year legacy in dermatology, but their ambition and transformative journey is beyond exhilarating. I look very much forward to applying my experience and perspective to support the company’s commitment to advancing care for patients with dermatological diseases.”


Becki Morison, EVP Global Product Strategy and International Operations with LEO Pharma comments:

“I am very pleased that such a strong, international profile in the dermatology space has decided to join LEO Pharma. With him on board we are adding extensive clinical experience and strong understanding of patients’ needs into our medical affairs work. Alexander will certainly strengthen a dermatologic mindset across our organization and ensure that we always put patient needs at the core as we continue to make a fundamental difference for those who need us most in medical dermatology. I am thrilled to welcoming Alexander to our team and looking forward to seeing his contributions to Global Medical Affairs and to our organization.”


Professor Egeberg will start in his new role January 1, 2024, reporting to Becki Morison. He will remain affiliated with the Department of Dermatology at Bispebjerg Hospital, and the University of Copenhagen to ensure that the patients’ needs, and the voice of the medical community remains deeply embedded in the core values and practices of the company going forward.

About LEO Pharma

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 4,200 people, serving millions of patients across the world. In 2023, the company generated net sales of DKK 11.4 billion


Henrik Heskjaer

Director, Global External Communications
Tel: +45 3140 6180